Overview

A Study of Tirzepatide (LY3298176) to Assess Glycemic Control in Adults With Type 2 Diabetes Switching From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)

Status:
Not yet recruiting

Trial end date:
2023-10-09

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide/GIP/GLP-1 RA agonist) in participants with type 2 diabetes (T2D).

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide